glp 1 cardiovascular risk reduction Effect of GLP-1 on Factors 3. Integration of GLP-1RA or

Saito-Diaz, K

oral semaglutide (Rybelsus) is licensed only for type 2 diabetes, not weight management

[22] [23] Other digestive symptoms may include mild abdominal discomfort, occasional vomiting, or changes in bowel habits (either constipation or loose stools)

This finding related to combination therapy concurs with the study by Shankar and colleagues, which showed that patients who received combination therapy with a CTLA-4 inhibitor and PD-1/PD-L1 inhibitor had an increased risk for multisystem immune-related adverse events

However, this same mechanism can produce gastrointestinal side effects that may resemble some symptoms of gastroparesis